Lapatinib therapy for patients with advanced renal cell carcinoma

Abstract

Lapatinib is an oral dual inhibitor of EGFR and HER2, the coexpression of which is associated with metastatic disease in patients with renal cell carcinoma. A recent randomized phase III trial of lapatinib versus hormone therapy was conducted in patients with cytokine-refractory metastatic renal cell carcinoma and tumors overexpressing EGFR and/or HER2. The study included 416 such patients who received either lapatinib (n = 209) or hormone therapy (n = 207). No benefit in time to progression, which was the primary end point of the study, or other clinical outcome measures, could be demonstrated for lapatinib therapy. A nonsignificant numerical advantage in time to progression was observed in patients with EGFR overexpression in the primary tumor (immunohistochemistry score 3+), suggesting that lapatinib could be of benefit in this subset of patients. This commentary emphasizes the need for further prospective studies to demonstrate the benefit of lapatinib therapy in patients with metastatic renal cell carcinoma.

A Novel Prognostic Model for Clear Cell Renal Cell Carcinoma with Differentially Expressed Immune-related lncRNA Pairs Based on the Cancer Genome Atlas

“…A Phase research veri ed that the mTOR inhibitor, temsirolimus, is another option of rst-line therapy [40]. In addition, EGFR and HER2 inhibitor lapatinib has been taken into ccRCC treatment in recent years [41]. This risk model illustrated that high risk patients were more signi cantly included in the advanced stage and grade, and they had lower IC50 level of sunitinib and temsirolimus.…”

Bioinformatics analysis and experimental verification of the cancer-promoting effect of DHODH in clear cell renal cell carcinoma

“…Lapatinib is an orally administered, reversible epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER-2) tyrosine kinase inhibitor. Clinical studies have revealed that lapatinib had promising results regarding RCC treatment 45 , 46 . The Ser/Thr protein kinase, CK2, is involved in important pathways related to tumor progression, such as Hedgehog and Wnt 47 .…”

Klarzelliges Nierenzellkarzinom

“…Bereits bei der ersten Interimsanalyse nach median gut einjährigem Follow-up hatte sich die Doublette der Referenztherapie bei den koprimären Endpunkten progressionsfreies (PFS) und Gesamtüberleben (OS) sowie der Ansprechrate als eindeutig überlegen erwiesen 1 . Prof. Brian Rini, Nashville (USA), stellte auf dem Annual Meeting der American Society of Clinical Oncology (ASCO) eine aktualisierte Auswertung nach längerer Nachbeobachtung von median 67,2 Monaten vor 2 . Danach verbesserte sich das PFS von 11,1 Monaten unter Sunitinib allein auf 15,7 Monate unter Pembrolizumab/Axitinib, entsprechend einer Risikoreduktion für Progress und Tod um 31 % (HR: 0,69).…”